Drugs / Afegostat
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00875160 | Apr → Jul 2009 | Gaucher disease type I | Amicus Therapeutics | Terminated | No outcome recorded Stop: Enrollment |
| Phase 23 trials | ||||||
| Phase 2 | NCT00813865 | May 2009 → May 2012 | Gaucher disease type I | Amicus Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT00446550 | Jun 2008 → Aug 2009 | Gaucher disease type I | Amicus Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT00433147 | Mar 2007 → Feb 2008 | Gaucher disease type I | Amicus Therapeutics | Completed | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Afegostat | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00433147 ↗ |
| Known as | Afegostat tartrate | “Afegostat tartrate (also known as AT2101 or isofagomine tartrate) is designed to act as a pharmacological chaperone by selectively binding to misfolded β-glucocerebrosidase...” NCT00433147 ↗ |
| Known as | AT2101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00875160 ↗ |
| Known as | HGT-3410 | ChEMBL registry synonym — accepted as the source's own label CHEMBL206468 ↗ |
| Known as | Isofagomine | ChEMBL registry synonym — accepted as the source's own label CHEMBL206468 ↗ |
| Known as | Isofagomine tartrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL206468 ↗ |
| Known as | Plicera | ChEMBL registry synonym — accepted as the source's own label CHEMBL206468 ↗ |
| Action | Restore | “intended to restore GCase activity” NCT00433147 ↗ |
| Modality | Other / unclassified | “Afegostat tartrate (also known as AT2101 or isofagomine tartrate) is designed to act as a pharmacological chaperone” NCT00446550 ↗ |
| Route | Oral | “Afegostat tartrate was administered orally during the 4-week treatment period.” NCT00433147 ↗ |
| Target | GBA1 | “Beta-glucocerebrosidase stabiliser” CHEMBL206468 ↗ |